BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

776 related articles for article (PubMed ID: 10484079)

  • 21. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
    Schaefer EJ; McNamara JR; Tayler T; Daly JA; Gleason JL; Seman LJ; Ferrari A; Rubenstein JJ
    Am J Cardiol; 2004 Jan; 93(1):31-9. PubMed ID: 14697462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of both the apical sodium-dependent bile acid transporter and HMG-CoA reductase markedly enhances the clearance of LDL apoB.
    Telford DE; Edwards JY; Lipson SM; Sutherland B; Barrett PH; Burnett JR; Krul ES; Keller BT; Huff MW
    J Lipid Res; 2003 May; 44(5):943-52. PubMed ID: 12562847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Different effect of simvastatin and atorvastatin on key enzymes involved in VLDL synthesis and catabolism in high fat/cholesterol fed rabbits.
    Verd JC; Peris C; Alegret M; Díaz C; Hernández G; Vázquez M; Adzet T; Laguna JC; Sánchez RM
    Br J Pharmacol; 1999 Jul; 127(6):1479-85. PubMed ID: 10455299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates.
    Forster LF; Stewart G; Bedford D; Stewart JP; Rogers E; Shepherd J; Packard CJ; Caslake MJ
    Atherosclerosis; 2002 Sep; 164(1):129-45. PubMed ID: 12119202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of decreased plasma cholesterol by atorvastatin treatment on erythrocyte mechanical properties.
    Uyuklu M; Meiselman HJ; Baskurt OK
    Clin Hemorheol Microcirc; 2007; 36(1):25-33. PubMed ID: 17211059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells.
    Scharnagl H; Schinker R; Gierens H; Nauck M; Wieland H; März W
    Biochem Pharmacol; 2001 Dec; 62(11):1545-55. PubMed ID: 11728391
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of hypolipidemic drugs on key enzyme activities related to lipid metabolism in normolipidemic rabbits.
    Alegret M; Verd JC; Díaz C; Hernández G; Adzet T; Sánchez RM; Laguna JC
    Eur J Pharmacol; 1998 Apr; 347(2-3):283-91. PubMed ID: 9653895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative effects of HMG-CoA reductase inhibitors on apo B production in the casein-fed rabbit: atorvastatin versus lovastatin.
    Auerbach BJ; Krause BR; Bisgaier CL; Newton RS
    Atherosclerosis; 1995 Jun; 115(2):173-80. PubMed ID: 7661876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dose-response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies.
    Wierzbicki AS; Mikhailidis DP
    Int J Cardiol; 2002 Jul; 84(1):53-7. PubMed ID: 12104065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice.
    de Haan W; van der Hoogt CC; Westerterp M; Hoekstra M; Dallinga-Thie GM; Princen HM; Romijn JA; Jukema JW; Havekes LM; Rensen PC
    Atherosclerosis; 2008 Mar; 197(1):57-63. PubMed ID: 17868678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of ER-27856, a novel squalene synthase inhibitor, on plasma cholesterol in rhesus monkeys: comparison with 3-hydroxy-3-methylglutaryl-coa reductase inhibitors.
    Hiyoshi H; Yanagimachi M; Ito M; Ohtsuka I; Yoshida I; Saeki T; Tanaka H
    J Lipid Res; 2000 Jul; 41(7):1136-44. PubMed ID: 10884296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HMG-CoA reductase inhibitors, simvastatin and atorvastatin, downregulate ABCG1-mediated cholesterol efflux in human macrophages.
    Wang W; Song W; Wang Y; Chen L; Yan X
    J Cardiovasc Pharmacol; 2013 Jul; 62(1):90-8. PubMed ID: 23846804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Guar gum effects on plasma low-density lipoprotein and hepatic cholesterol metabolism in guinea pigs fed low- and high-cholesterol diets: a dose-response study.
    Fernandez ML; Sun DM; Tosca M; McNamara DJ
    Am J Clin Nutr; 1995 Jan; 61(1):127-34. PubMed ID: 7825524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels.
    Alaupovic P; Heinonen T; Shurzinske L; Black DM
    Atherosclerosis; 1997 Aug; 133(1):123-33. PubMed ID: 9258416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinical relevance of low-density-lipoproteins size modulation by statins.
    Rizzo M; Berneis K
    Cardiovasc Drugs Ther; 2006 Jun; 20(3):205-17. PubMed ID: 16775666
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes.
    Qin W; Infante J; Wang SR; Infante R
    Biochim Biophys Acta; 1992 Jul; 1127(1):57-66. PubMed ID: 1627634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short- and long-term effects of atorvastatin, lovastatin and simvastatin on the cellular metabolism of cholesteryl esters and VLDL secretion in rat hepatocytes.
    Isusi E; Aspichueta P; Liza M; Hernández ML; Díaz C; Hernández G; Martínez MJ; Ochoa B
    Atherosclerosis; 2000 Dec; 153(2):283-94. PubMed ID: 11164417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
    Baldassarre S; Scruel O; Deckelbaum RJ; Dupont IE; Ducobu J; Carpentier YA
    Int J Cardiol; 2005 Oct; 104(3):338-45. PubMed ID: 16186066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamics and pharmacokinetic-pharmacodynamic relationships of atorvastatin, an HMG-CoA reductase inhibitor.
    Stern RH; Yang BB; Hounslow NJ; MacMahon M; Abel RB; Olson SC
    J Clin Pharmacol; 2000 Jun; 40(6):616-23. PubMed ID: 10868312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.